UPDATE: Kronos Bio Inc. (KRON) Prices 13.16M Share IPO at $19/Sh

Kronos Bio, Inc. (NASDAQ: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the pricing of its initial public offering of 13,157,895 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Kronos Bio from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $250.00 million. All of the shares are being offering by Kronos Bio. In addition, Kronos Bio has granted the underwriters a 30-day option to purchase up to an additional 1,973,684 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on October 9, 2020, under the ticker symbol “KRON.” The offering is expected to close on October 14, 2020, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies, Cowen and Piper Sandler are acting as joint book-running managers for the offering.

You May Also Be Interested In

• Entrata (ENT) files for proposed IPO
• Electra Therapeutics files for proposed IPO
• Tencent Music plans senior unsecured notes offering